Journal Basic Info
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.Major Scope
- Immunotherapy
- Kidney Cancer
- Bladder Cancer
- Thoracic Oncology
- Chemoprevention
- Endoscopy Methods
- Sarcomas
- Haemato-Oncology
Abstract
Citation: Clin Oncol. 2017;2(1):1253.DOI: 10.25107/2474-1663.1253
Single Ablative Intravesical Electromotive Mitomycin C Administration for Small Non-Muscle-Invasive Bladder Cancer: A Prospective Study
Karel Decaestecker, Nicolaas Lumen, Christel Van Camp and Willem Oosterlinck
Department of Urology, Ghent University Hospital, Ghent, Belgium
*Correspondance to: Willem Oosterlinck
PDF Full Text Research Article | Open Access
Abstract:
Aim: To explore the effect of Electromotive Drug Administration Of Mitomycin C (EMDA-MMC) using a single dose of intravesical mitomycin C (MMC) to avoid transurethral resection (TURBT) for small non-muscle-invasive bladder cancer. Material and
Methods: All patients presenting small papillary bladder tumors were proposed to undergo a single EMDA-MMC session with 60mg MMC before planning TURBT. The end point is complete disappearance of all papillary tumors at 2 to 4 weeks after EMDA-MMC.Results: Thirty-six sessions were given to 32 patients. In general the treatment was well supported, except for two patients who had severe bladder spasms, resulting in early evacuation of the MMC. Complete response occurred in 28% (10/36 sessions). In 4 sessions with multiple tumors some tumors disappeared while others remained. In 61% (22/36) the tumors remained unchanged.
Conclusion: A single EMDA-MMC in small papillary bladder tumors gives insufficient ablative effect.
Keywords:
Electromotive drug administration; Mitomycin; Intravesical chemotherapy; Urothelial bladder cancer; Chemoresection; Superficialbladder tumors; Non-muscle-invasivebladder cancer
Cite the Article:
Decaestecker K, Lumen N, Van Camp C, Oosterlinck W. Single Ablative Intravesical Electromotive Mitomycin C Administration for Small Non-Muscle- Invasive Bladder Cancer: A Prospective Study. Clin Oncol. 2017; 2: 1253.